Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Gamida Cell

Nasdaq:GMDA
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GMDA
Nasdaq
$109M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • Gamida Cell has significant price volatility in the past 3 months.
GMDA Share Price and Events
7 Day Returns
3.5%
NasdaqGM:GMDA
5.2%
US Biotechs
10.5%
US Market
1 Year Returns
-71.2%
NasdaqGM:GMDA
0%
US Biotechs
-11.5%
US Market
GMDA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Gamida Cell (GMDA) 3.5% -24.8% -24.8% -71.2% - -
US Biotechs 5.2% -6.5% -8.7% 0% 6.2% -10.4%
US Market 10.5% -15.4% -21.4% -11.5% 5.4% 18.1%
1 Year Return vs Industry and Market
  • GMDA underperformed the Biotechs industry which returned 0% over the past year.
  • GMDA underperformed the Market in United States of America which returned -11.5% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is Gamida Cell undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Gamida Cell. This is due to cash flow or dividend data being unavailable. The share price is $3.25.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Gamida Cell's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Gamida Cell's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:GMDA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.17
NasdaqGM:GMDA Share Price ** NasdaqGM (2020-03-27) in USD $3.25
United States of America Biotechs Industry PE Ratio Median Figure of 37 Publicly-Listed Biotechs Companies 15.4x
United States of America Market PE Ratio Median Figure of 2,939 Publicly-Listed Companies 12.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Gamida Cell.

NasdaqGM:GMDA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:GMDA Share Price ÷ EPS (both in USD)

= 3.25 ÷ -1.17

-2.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gamida Cell is loss making, we can't compare its value to the US Biotechs industry average.
  • Gamida Cell is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Gamida Cell's expected growth come at a high price?
Raw Data
NasdaqGM:GMDA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
37.8%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 0.96x
United States of America Market PEG Ratio Median Figure of 2,005 Publicly-Listed Companies 1x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Gamida Cell, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Gamida Cell's assets?
Raw Data
NasdaqGM:GMDA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.04
NasdaqGM:GMDA Share Price * NasdaqGM (2020-03-27) in USD $3.25
United States of America Biotechs Industry PB Ratio Median Figure of 429 Publicly-Listed Biotechs Companies 2.53x
United States of America Market PB Ratio Median Figure of 5,148 Publicly-Listed Companies 1.26x
NasdaqGM:GMDA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:GMDA Share Price ÷ Book Value per Share (both in USD)

= 3.25 ÷ 1.04

3.13x

* Primary Listing of Gamida Cell.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gamida Cell is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Gamida Cell's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Gamida Cell has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Gamida Cell expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Gamida Cell expected to grow at an attractive rate?
  • Gamida Cell's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Gamida Cell's earnings growth is expected to exceed the United States of America market average.
  • Unable to compare Gamida Cell's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:GMDA Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:GMDA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 37.8%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:GMDA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:GMDA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 220 41 3
2023-12-31 142 -15 3
2022-12-31 94 -40 3
2021-12-31 44 -46 -67 5
2020-12-31 1 -65 -62 5
2020-03-28
NasdaqGM:GMDA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -38 -34
2019-09-30 -35 -42
2019-06-30 -30 -42
2019-03-31 -29 -61
2018-12-31 -26 -53
2018-09-30 -22 -36
2018-06-30 -22 -30
2018-03-31 -19 -22
2017-12-31 -17 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Gamida Cell's earnings are expected to grow significantly at over 20% yearly.
  • Unable to determine if Gamida Cell is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:GMDA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Gamida Cell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:GMDA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.94 0.95 0.92 2.00
2023-12-31 -0.31 0.12 -0.74 2.00
2022-12-31 -0.90 -0.66 -1.14 2.00
2021-12-31 -1.76 -1.34 -2.50 3.00
2020-12-31 -1.72 -1.31 -2.04 4.00
2020-03-28
NasdaqGM:GMDA Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.17
2019-09-30 -1.66
2019-06-30 -2.43
2019-03-31 -5.49
2018-12-31 -10.53
2018-09-30 -52.26
2018-06-30 -43.73
2018-03-31 -31.51
2017-12-31 -27.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Gamida Cell will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Gamida Cell's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Gamida Cell has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Gamida Cell performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Gamida Cell's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Gamida Cell does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Gamida Cell's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Gamida Cell's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Gamida Cell's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Gamida Cell Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:GMDA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -34.35 16.78 31.46
2019-09-30 -42.27 16.79 26.56
2019-06-30 -42.00 14.60 24.33
2019-03-31 -61.05 13.76 24.27
2018-12-31 -52.93 11.60 22.05
2018-09-30 -36.05 8.73 21.47
2018-06-30 -30.17 7.27 19.71
2018-03-31 -21.74 5.24 16.41
2017-12-31 -19.01 4.47 15.02
2016-12-31 -22.67 4.61 19.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Gamida Cell has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Gamida Cell has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Gamida Cell improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Gamida Cell's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Gamida Cell has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Gamida Cell's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Gamida Cell's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Gamida Cell is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Gamida Cell's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Gamida Cell's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Gamida Cell has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Gamida Cell Company Filings, last reported 2 months ago.

NasdaqGM:GMDA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 34.98 0.00 55.40
2019-09-30 48.92 0.00 68.12
2019-06-30 20.55 0.00 41.70
2019-03-31 13.15 0.00 50.26
2018-12-31 24.69 0.00 60.69
2018-09-30 -4.86 0.00 23.68
2018-06-30 3.96 0.00 28.64
2018-03-31 22.96 0.00 41.08
2017-12-31 22.96 0.00 41.08
2016-12-31 10.96 0.00 18.06
  • Gamida Cell has no debt.
  • Gamida Cell has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Gamida Cell has sufficient cash runway for 1.4 years based on current free cash flow.
  • Gamida Cell has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 36.7% each year.
X
Financial health checks
We assess Gamida Cell's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Gamida Cell has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Gamida Cell's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Gamida Cell dividends.
If you bought $2,000 of Gamida Cell shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Gamida Cell's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Gamida Cell's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:GMDA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 65 Stocks 2.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1949 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:GMDA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-03-28

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Gamida Cell has not reported any payouts.
  • Unable to verify if Gamida Cell's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Gamida Cell's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Gamida Cell has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Gamida Cell's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Gamida Cell afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Gamida Cell has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Gamida Cell's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Julian Adams
COMPENSATION $2,232,000
AGE 64
TENURE AS CEO 2.3 years
CEO Bio

Dr. Julian Adams, Ph.D., serves as Executive Chairman of Elicio Therapeutics Inc. He serves as the Chief Executive Officer of Gamida Cell Ltd. since November 20, 2017. Dr. Adams was the President and Chief Science Officer at Clal Biotechnology Industries Ltd. since January 23, 2017 until 2019. Julian served as a Scientific Adviser at Clal Biotechnology Industries Ltd. since 2019 until 2019. He serves as a Scientific Advisor at the firm. He served as the President of Research & Development at Infinity Pharmaceuticals, Inc. from 2003 to January 6, 2017. He served the Senior Vice President of Research & Development at Infinity Pharmaceuticals, Inc. since October 2003 and also served as its Chief Scientific Officer from September 2006 to May 2010. From December 1999 to October 2003, he served as a Senior Vice President of Drug Discovery & Development at Millennium Pharmaceuticals, where he headed multiple global drug discovery and development programs, including the successful Velcade® (bortezomib) program. He joined Millennium Pharmaceuticals in December of 1999 following the Millennium's merger with LeukoSite Inc., where he served as a Senior Vice President of Research and Development. From 1994 to 1999, he served as an Executive Vice President of Research and Development at Proscript Inc. In 1987, he joined Boehringer Ingelheim, where he served in various senior positions in research and development including Director of Medicinal Chemistry. At the firm he was credited with the discovery of Viramune® (nevirapine) for HIV. He served as Senior Vice President of Clinical Development and Med at Cytomed, Inc. He served as the President of Infinity Pharmaceuticals, Inc. from September 2006 to October 2007. From 1982 to 1987, he served as a Medicinal Chemist of Merck in Montreal. He was the Chairman of Gamida Cell Ltd. since November, 2016 until September 18, 2018 and its Director since September 15, 2016. He serves as an Executive Chairman at the firm.He serves as an Executive Chairman and a Board Member at Curetech. He served as Chairman at CureTech Ltd. since May 14, 2017 until October 22, 2017. He was a Director of Pieris Pharmaceuticals, Inc. from July 25, 2016 until July 25, 2018 and serves as Director of Warp Drive Bio, LLC since July 2013. He has been a Member of Scientific Advisory Board at REVOLUTION Medicines, Inc. since December 13, 2016 and serves as its Senior Advisor. He serves as a Member of Scientific Advisory Board at Mediphase Venture Partners and Raze Therapeutics, Inc., Cleave Biosciences and Stand Up to Cancer. He served as Director of Neon Therapeutics Inc. since December 2017 until August 28, 2018. He served as a Director of Predix Pharmaceuticals, Inc. He served as Member of Advisory Board at Cytomed, Inc. He served as a Director of Predix Pharmaceuticals Holdings Inc. since September 2003 and Aileron Therapeutics Inc. since May 2011. He served as a Member of Scientific Advisory Board at BIND Therapeutics, Inc. since May 2011. He served as a Member of Scientific Advisory Board at DNIB Unwind, Inc., Sirtris Pharmaceuticals, Inc., Verastem, Inc. and Constellation Pharmaceuticals, Inc. He has been integrally involved in the discovery and development of a marketed drug Velcade. He is an Editor of a book on The Proteasome in Cancer. Dr. Adams has received many awards, including the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an Inventor on more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. Dr. Adams has more than 30 years of experience in drug discovery and development with a strong focus on cancer, oncology. Dr. Adams holds a PhD from the Massachusetts Institute of Technology in the field of Synthetic Organic Chemistry and a BS from the McGill University. Dr. Adams also received a Doctor of Science, honoris causa, from McGill University in 2012.

CEO Compensation
  • Julian's compensation has increased whilst company is loss making.
  • Julian's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Gamida Cell management team in years:

1.9
Average Tenure
49
Average Age
  • The average tenure for the Gamida Cell management team is less than 2 years, this suggests a new team.
Management Team

Julian Adams

TITLE
CEO & Director
COMPENSATION
$2M
AGE
64
TENURE
2.3 yrs

Shai Lankry

TITLE
Chief Financial Officer
COMPENSATION
$843K
AGE
43
TENURE
1.9 yrs

Ronit Simantov

TITLE
Chief Medical Officer
COMPENSATION
$912K
AGE
54
TENURE
2.8 yrs

Josh Hamermesh

TITLE
Chief Business Officer
COMPENSATION
$887K
AGE
47
TENURE
1.9 yrs

Tom Klima

TITLE
Chief Commercial Officer
COMPENSATION
$767K
AGE
47
TENURE
1.2 yrs

Tzvi Palash

TITLE
Chief Operating Officer
AGE
62
TENURE
1.7 yrs

Tracey Lodie

TITLE
Chief Scientific Officer
AGE
49
TENURE
0.8 yrs

Jaren Madden

TITLE
Vice President of Investor Relations & Corporate Communications
TENURE
1.7 yrs

Paul Nee

TITLE
Vice President of Marketing
TENURE
1.9 yrs

Naftali Brikashvili

TITLE
Senior Vice President Finance & Operations
Board of Directors Tenure

Average tenure and age of the Gamida Cell board of directors in years:

2.2
Average Tenure
60
Average Age
  • The average tenure for the Gamida Cell board of directors is less than 3 years, this suggests a new board.
Board of Directors

Robert Blum

TITLE
Independent Chairman of the Board
AGE
55
TENURE
1.5 yrs

Julian Adams

TITLE
CEO & Director
COMPENSATION
$2M
AGE
64
TENURE
3.6 yrs

Ken Moch

TITLE
Independent Director
AGE
64
TENURE
3.7 yrs

Nurit Benjamini

TITLE
Independent Director
AGE
52
TENURE
1.2 yrs

Ofer Gonen

TITLE
Independent Director
AGE
45
TENURE
5.2 yrs

Mike Perry

TITLE
Independent Director
AGE
60
TENURE
2.8 yrs

Shawn Tomasello

TITLE
Independent Director
AGE
60
TENURE
0.8 yrs

Steve Wills

TITLE
Independent Director
AGE
62
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. Jul 19 Buy Ai Biotechnology Llc Company 01. Jul 19 01. Jul 19 2,000,000 $5.00 $10,000,000
X
Management checks
We assess Gamida Cell's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Gamida Cell has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could The Gamida Cell Ltd. (NASDAQ:GMDA) Ownership Structure Tell Us Something Useful?

Insider Ownership Of Gamida Cell The definition of company insiders can be subjective, and does vary between jurisdictions. … Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. … Public Company Ownership We can see that public companies hold 22%, of the GMDA shares on issue.

Simply Wall St -

Company Info

Description

Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The company’s lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Details
Name: Gamida Cell Ltd.
GMDA
Exchange: NasdaqGM
Founded: 1998
$109,430,509
33,670,926
Website: http://www.gamida-cell.com
Address: Gamida Cell Ltd.
5 Nahum Heftsadie Street,
Givaat Shaul,
Jerusalem,
91340,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM GMDA Ordinary Shares Nasdaq Global Market US USD 26. Oct 2018
Number of employees
Current staff
Staff numbers
81
Gamida Cell employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/28 04:14
End of day share price update: 2020/03/27 00:00
Last estimates confirmation: 2020/03/02
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.